ADC Therapeutics SA Common Shares (ADCT)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 50/100 (MEDIUM), 18.1 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 5.37% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
- ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript
- ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Zynlonta Outlook
- ADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ...
- ADC Therapeutics Q2 Earnings Call Highlights
- ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
- ADC Therapeutics Announces New Employee Inducement Grant
- ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for ADC Therapeutics SA Common Shares.
Full ADCT Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.